Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.
- ET
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights. - Additional detail on the acquisition can be found here
Strengthened management team with appointments of neuro-oncologist Andrew Brenner, M.D. - Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call.
- The webcast will be available on the Company’s website for 90 days following the live call.